Tesamorelin 10mg/Ipamorelin 3mg
Janoshik
Batch TIPA-CA-26G-13
- Tesamorelin
- 10.87 mg
- Ipamorelin
- 3.53 mg
Tesamorelin 10mg / Ipamorelin 3mg Blend
Tesamorelin / Ipamorelin GH-Axis Blend
The Tesamorelin + Ipamorelin blend combines a GHRH analogue (Tesamorelin) with a selective ghrelin-receptor agonist (Ipamorelin), studied for complementary stimulation of the GH/IGF-1 axis.
This product is intended strictly for laboratory research use within the United States. It is not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable U.S. federal, state, and local regulations.
The Tesamorelin + Ipamorelin blend combines a GHRH analogue (Tesamorelin) with a selective ghrelin-receptor agonist (Ipamorelin), studied for complementary stimulation of the GH/IGF-1 axis.
Each component is independently characterized in the laboratory literature; the blend is studied as a combined preparation.
This blend combines Tesamorelin, a stabilized GHRH analogue, with Ipamorelin, a selective growth-hormone secretagogue. Research framing draws on the established literature for each peptide and on the complementary GHRH + secretagogue model of GH-axis stimulation.
The blend is studied as a combined preparation in GH/IGF-1 axis research models under structured conditions.
The blend is formulated from two independently studied GH-axis peptides with distinct research lineages — Tesamorelin as a GHRH analogue and Ipamorelin as a selective ghrelin-receptor agonist.
Research framing for the Tesamorelin + Ipamorelin blend draws on the combined literature of its components across GHRH-receptor and ghrelin-receptor signaling models of the GH/IGF-1 axis under controlled conditions.
3 of the 4 areas below are addressed directly by a paper cited on this page.
GHRH-receptor signaling (Tesamorelin)
Addressed on this page by Falutz 2010, Falutz 2010. The work appeared in J Clin Endocrinol Metab. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Falutz, J. et al. (2010) — Effects of tesamorelin (TH9507), a growth hormone–releasing factor analogue, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.
- Falutz, J. et al. (2010) — Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 95(9):4291–4304.
Selective ghrelin-receptor agonism (Ipamorelin)
Addressed on this page by Raun 1998. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Raun, K. et al. (1998) — Ipamorelin, the first selective growth hormone secretagogue.
GH/IGF-1 axis regulation research
No paper cited on this page reports on axis or regulation. This heading marks where Tesamorelin 10mg / Ipamorelin 3mg Blend is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Combined secretagogue frameworks
Addressed on this page by Raun 1998. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Raun, K. et al. (1998) — Ipamorelin, the first selective growth hormone secretagogue.
The references section of this page cites 3 primary papers published between 1998 and 2010 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for Tesamorelin 10mg / Ipamorelin 3mg Blend, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
Tesamorelin 10mg / Ipamorelin 3mg Blend is commonly described online in connection with muscle growth, fat loss and improved recovery. In the research literature the same compound is filed under GHRH-receptor signaling (Tesamorelin), selective ghrelin-receptor agonism (Ipamorelin) and GH/IGF-1 axis regulation research.
Of the 3 papers cited on this page, published between 1998 and 2010, 2 report work in human participants — Falutz 2010 and Falutz 2010. Human data for a molecule is not the same as evidence for material supplied as a research compound: published trials use pharmaceutical-grade product under medical supervision at defined doses. What is established for the material sold here is its measured purity and content per lot.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
The lot code printed on the vial matches the code on the certificate for Tesamorelin 10mg / Ipamorelin 3mg Blend. Matching the two is what confirms the unit in hand came from the batch that was tested — a certificate not tied to a lot code proves nothing about any particular unit.
Researchers who buy Tesamorelin 10mg / Ipamorelin 3mg Blend in the United States through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
- Lyophilized storage
- −20 °C long-term; stable at room temperature in transit
- After reconstitution
- 2–8 °C
- Light
- Protect from UV and direct light
- Freeze-thaw
- Avoid repeated cycles
- Vehicle
- Bacteriostatic water in most published protocols
- Format
- Lyophilized powder
Tesamorelin 10mg / Ipamorelin 3mg Blend is a co-lyophilized blend — more than one compound freeze-dried together in a single vial. Handling follows the least stable component rather than an average, and the same is true of storage: the constraint that binds is whichever compound in the vial is most sensitive.
Reconstituting a blend does not separate its components, so a blend cannot be split into its parts after the fact. That is why per-component content verification matters more here than a single blended purity figure — the ratio inside the vial is fixed at manufacture and cannot be corrected downstream.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
- 1 × sealed glass vial in the strength selected (13mg / 1 Vial, 13mg / 5-Pack, 13mg / 10-Pack available), batch-labelled
- The batch-linked Certificate of Analysis for the exact lot shipped
- Discreet outer packaging with no product names on the exterior
- FedEx, tracked, typically 1–3 business days domestically
- Bacteriostatic water or any other reconstitution vehicle
- Syringes, needles or filters
- Dosing, administration or protocol guidance of any kind
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of tesamorelin ipamorelin blend. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Effects of tesamorelin (TH9507), a growth hormone–releasing factor analogue, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.
PubMedEffects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 95(9):4291–4304.
PubMedRelated
You May Also Like
Next-generation GLP receptor agonist studied for metabolic signaling and nutrient partitioning pathways
From$79.99
Dual incretin receptor agonist studied for glucose regulation, metabolic signaling, and weight pathway research
From$39.99
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
From$59.99
Long-acting amylin analog engineered for appetite signaling, metabolic control, and energy balance research
From$99.99